Juno Therapeutics announced the pricing of its initial public offering of 11,022,917 shares of common stock at a price to the public of $24.00 per share.
In addition, Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any.
|Searching for more deal information? Current Partnering offers the following options:|
Juno Therapeutics’ common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol “JUNO” on December 19, 2014.
The offering is expected to close on December 23, 2014, subject to customary closing conditions.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies
Report: Top 50 Big Biotech Partnering and M&A Deal Trends